WATCH: @JavierCortesMD, highlights KEYNOTE-522 data with pembrolizumab in triple-negative breast cancer. #bcsm# #oncology#
See more insights on our breast cancer page!
WATCH: @PTarantinoMD, of @DanaFarber, highlights the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer. #bcsm# #oncology#
See our HER2-positive breast cancer page for more insights!
📽️ Jacob Stephen Thomas, MD, of @KECKSchool_USC unpacks the safety and efficacy data from a phase 2 study of ipatasertib plus pembrolizumab in the first-line treatment of patients with metastatic HNSCC presented at @ASCO #ASCO26#